.Attributes Medication, Posted online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the empirical SCRUM-Japan GOZILA research study, after a median follow-up of 11 months, patients with metastatic gastrointestinal tumors that received biomarker-matched therapies based upon flowing tumor DNA profiling presented a better clinical advantage than those getting unmatched treatment.